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Corticosteroids influence the development and function of the heart and its response to 
injury and pressure overload via actions on glucocorticoid (GR) and mineralocorticoid (MR) 
receptors. Systemic corticosteroid concentration depends largely on the activity of the 
hypothalamic–pituitary–adrenal (HPA) axis, but glucocorticoid can also be regenerated from 
intrinsically inert metabolites by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1), selectively increasing glucocorticoid levels within cells and tissues. Extensive studies 
have revealed the roles for glucocorticoid regeneration by 11β-HSD1 in liver, adipose, brain 
and other tissues, but until recently, there has been little focus on the heart. This article 
reviews the evidence for glucocorticoid metabolism by 11β-HSD1 in the heart and for a role of 
11β-HSD1 activity in determining the myocardial growth and physiological function. We also 
consider the potential of 11β-HSD1 as a therapeutic target to enhance repair after myocardial 
infarction and to prevent the development of cardiac remodelling and heart failure.
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Introduction
The major physiological adrenocorticosteroid hor­
mones, glucocorticoids (cortisol in most animals and 
corticosterone in rats and mice) and mineralocorticoids 
(aldosterone) are vital for normal cardiovascular function. 
They regulate blood pressure (Hunter & Bailey 2015) and 
vascular tone (Ullian 1999, Dover et al. 2007, Hadoke et al. 
2009), as well as heart rhythm and contractility (Lefer 1967, 
1968, Penefsky & Kahn 1971, Ouvrard­Pascaud et al. 2005, 
Cruz­Topete et  al. 2016). Under pathological conditions, 
rapid corticosteroid release in response to hypothalamic–
pituitary–adrenal (HPA) axis activation is an early response 
to cardiovascular insult, including after myocardial 
infarction (MI). In the acute period, post­MI corticosteroids 
are cardioprotective and suppress the early inflammatory 
response to injury (Libby et  al. 1973, Skyschally et  al. 
2004). However, sustained excessive glucocorticoid release 
from the adrenals, for example in Cushing’s syndrome, is 
associated with detrimental cardiac outcomes, including 
myocardial ischaemia and hypertrophy, and in rare cases, 
with loss of cardiomyocytes and dilated cardiomyopathy 
(Peppa et  al. 2009, Shibusawa et  al. 2015, Frustaci et  al. 
2016). Chronic stress associates with cardiovascular disease 
(Kumari et al. 2011), as does pharmacological glucocorticoid 
treatment (Wei et al. 2004, Souverein et al. 2004).
Corticosteroids influence cell behaviour primarily 
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g a gray and others 11β-HSD1 and the heart
(GR) and mineralocorticoid (MR) receptors. In the heart, 
activation of both GR and MR has an impact on cardiac 
development, physiology and pathophysiology (reviewed 
in Oakley & Cidlowski 2015 and Richardson et al. 2016). GR 
and MR are highly related and belong to the nuclear receptor 
family of transcriptional regulators (Biddie et  al. 2010), 
although some corticosteroid actions may be mediated 
by non­classical signalling through cell­surface receptors 
(Mihailidou & Funder 2005, Samarasinghe et al. 2012). The 
GR binds glucocorticoids with 10­ to 30­fold lower affinity 
than the MR, but is relatively selective for glucocorticoid 
compared with mineralocorticoid binding (Mihailidou & 
Funder 2005, Samarasinghe et al. 2012). The MR has high 
affinity for both mineralocorticoids and glucocorticoids, 
but as glucocorticoids typically circulate at levels 100­fold 
higher than those of mineralocorticoids, the MR is likely to 
be constitutively occupied by glucocorticoids even at daily 
nadir levels. Downstream signalling may differ depending 
on which ligand occupies the receptor and, depending 
on prevailing conditions, glucocorticoids can behave as 
agonists or antagonists at the MR (reviewed in Funder 
2012). Access of mineralocorticoids to the MR depends 
on specific mechanisms that regulate the intracellular 
availability of adrenocorticosteroid hormones (Funder 
et al. 1988). These include the extent of protein binding in 
the plasma and in the heart itself (Bolton et al. 2014, Schafer 
et  al. 2015) and the activity of transporters that actively 
extrude steroids from the cell. However, glucocorticoids 
also undergo intracellular metabolism, and the capacity of 
individual cells to metabolise glucocorticoids is a critical 
factor in determining the extent (and indeed selectivity) 
of MR and GR activation (Funder et al. 1988, Odermatt & 
Kratschmar 2012, Chapman et al. 2013a).
11β-HSD enzymes
11β­hydroxysteroid dehydrogenase (11β­HSD) catalyses 
the intracellular interconversion of the glucocorticoids 
Figure 1
Adrenocorticosteroids, 11β-HSD1 and the heart. Hypothalamic–pituitary–adrenal (HPA) axis-derived glucocorticoids (cortisol in man, corticosterone in 
rats and mice) and the mineralocorticoid – aldosterone – compete for binding to cardiac glucocorticoid (GR) and mineralocorticoid receptors (MR). 
Glucocorticoids are also regenerated within the heart from circulating inert metabolites (cortisone in man and 11-dehydrocorticosterone (11-DHC) in  
rats and mice) by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), when it is expressed alongside hexose-6-phosphate dehydrogenase (H6PDH).  
As the glucocorticoid concentration ([cort]) normally far exceeds that of aldosterone ([aldo]), GR and MR are usually occupied by glucocorticoids. 
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) inactivates glucocorticoids, but unlike other MR target tissues, there is normally little or no 
dehydrogenase activity in the heart. Inactivation of glucocorticoids by 11β-HSD2 activity elsewhere in the body, largely in the kidney, generates the inert 
precursors that, on entering the circulation, become available for glucocorticoid regeneration and GR/MR activation in cells that express 11β-HSD1. 
In the healthy heart, 11β-HSD1 immunoreactivity (inset panel) is localised to vascular smooth muscle (VSM), fibroblasts (F) and also cardiomyocytes (CM) 
in a fixed section from mouse left ventricle. The 11β-HSD1 antibody is a sheep anti-mouse polyclonal generated in house (De Sousa Peixoto et al. 2008). 
Staining is notably absent in endothelial cells (EC) lining the vascular wall. A negative control of the same section generated using sheep IgG is shown in 
the inset panel. From S J McSweeney, PhD thesis, 2010 (McSweeney 2010). 11β-HSD1 expression can be increased by glucocorticoids, by pro-inflammatory 
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g a gray and others 11β-HSD1 and the heart
cortisol and corticosterone with their inert 11­keto forms 
(cortisone and 11­dehydrocorticosterone (11­DHC), 
respectively). 11β­HSD type 2 (11β­HSD2) is a high­
affinity (nanomolar KM), low­capacity NAD­dependent 
dehydrogenase (Albiston et al. 1994, Brown et al. 1996) 
that inactivates the glucocorticoids (Fig.  1). 11β­HSD1 
shares less than 30% homology with 11β­HSD2 (Lakshmi 
& Monder 1988, Agarwal et al. 1989) and is more widely 
distributed than 11β­HSD2. Under normal conditions, it 
is co­expressed at the luminal border of the endoplasmic 
reticulum alongside hexose­6­phosphate dehydrogenase 
(H6PDH) (Atanasov et  al. 2008) that provides the 
co­substrate NADPH (Bujalska et  al. 2005). This drives 
the oxo­reductase activity of 11β­HSD1, re­activating 
the glucocorticoids (Atanasov et  al. 2004, Bujalska 
et  al. 2005, Lavery et  al. 2006, Chapman et  al. 2013a) 
(Fig.  1). 11β­HSD1 has low affinity for glucocorticoids 
(micromolar KM) relative to 11β­HSD2, but where H6PDH 
is genetically deleted (Lavery et al. 2006) or where cells 
are disrupted so that NADPH cannot be generated in close 
proximity to 11β­HSD1, it switches from predominantly 
oxo­reductase to dehydrogenase activity and this 
inactivates rather than regenerates glucocorticoids 
(Atanasov et al. 2004). Activity of 11β­HSD1 (largely in the 
liver) and 11β­HSD2 (largely in the kidney) determines 
active and keto­isoform concentrations in the systemic 
circulation, but the variability in the activity of 11β­HSD 
enzymes at the level of target cells adds a cell­specific 
dimension to the control of steroid action (Chapman 
et al. 2013a). To date, there has been relatively little focus 
on the capacity of the myocardium or of its component 
cells to metabolise corticosteroids.
11β-HSD2 and MR activation in the heart
In mineralocorticoid target tissues, 11β­HSD2 is expressed 
alongside the MR, where its activity reduces the availability 
of glucocorticoid, permitting aldosterone to compete for 
binding to the MR (Edwards et al. 1988, Funder et al. 1988). 
The clinical efficacy of MR antagonists after MI (Pitt et al. 
2003) and in heart failure (Pitt et al. 1999, Zannad et al. 
2011, 2012) are attributed, at least in part, to blockade of 
MR activation in the heart. A recent preclinical study in 
adrenalectomised rats has shown that mineralocorticoids 
regulate cardiac electrical function through the activation 
of MR (Cruz­Topete et  al. 2016). However, the weight 
of evidence suggests that there is normally little or no 
11β­HSD2 activity in the heart (Walker et  al. 1991, 
Whorwood et  al. 1992), except perhaps in vascular 
endothelium (Walker et al. 1991, Smith et al. 1996). This 
was confirmed in a recent in vivo study on patients under­
going diagnostic coronary angiography that failed to find 
any evidence for inactivation of the stable isotope tracer 
9,11,12,12­[2H]4­cortisol across the human heart (Iqbal 
et al. 2014). Furthermore, infusion of the MR antagonist 
canrenoate in the same patients resulted in the elevation 
of cortisol collected from the coronary sinus. These data 
support the view that the cardiac MR is normally occupied 
by glucocorticoid, rather than by aldosterone. However, 
this situation may change in pathological conditions, 
including hypoxia (Klusonova et al. 2009), in which there 
is evidence for enhancement of 11β­HSD2 activity and 
expression (Chai et al. 2010, Chapman et al. 2013a), that 
may allow aldosterone to compete for binding to the MR. 
Selective overexpression of 11β­HSD2 in cardiomyocytes 
leads to MR­dependent hypertrophy and fibrosis in mice 
(Qin et al. 2003), showing potential for a role in cardiac 
pathology. Global 11β­HSD2 knockout mice have cardiac 
hypertrophy and fibrosis but, as these mice are also 
hypertensive (Kotelevtsev et  al. 1999), any phenotype 
that is specifically due to lack of 11β­HSD2 in the heart 
has proved impossible to dissect. Generation of mice 
with targeted 11β­HSD2 deletion in cardiomyocytes and 
other cardiac cells would provide a more definitive answer 
regarding the role of dehydrogenase activity in cardiac 
physiology and pathology.
Glucocorticoid regeneration by 11β-HSD1 in 
the heart
11β­HSD1 is more widely expressed in the body than 
11β­HSD2, but tissue expression of 11β­HSD1 is often 
reported to be low. This is also the case in the heart or at 
least in whole ventricular homogenates (Walker et al. 1991, 
White et al. 2016). However, immunoreactive 11β­HSD1 
can be localised to cardiomyocytes, to interstitial and 
adventitial fibroblasts (Brereton et al. 2001) and to vascular 
smooth muscle in murine heart (Fig.  1) (McSweeney 
2010). We have found that targeted deletion of 11β­HSD1 
in cardiomyocytes and vascular smooth muscle cells leads 
to a significant reduction in Hsd11b1 gene expression 
in the mouse heart, confirming its expression in these 
cells (White et  al. 2016). Although endothelial cells in 
culture are reported to have 11β­HSD1 activity (Brem 
et  al. 1998), previous studies have concluded that the 
11β­HSD enzyme in aortic endothelial cells is primarily 
a dehydrogenase, with oxo­reductase activity limited to 
the smooth muscle cell compartment of the vascular wall 
(Walker et al. 1991, Dover et al. 2007). Immunostaining 
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g a gray and others 11β-HSD1 and the heart
(Fig.  1). Fibroblasts are among the most abundant cells 
in the heart, and transcriptomic analysis has revealed 
that expression of Hsd11b1 is high in cardiac fibroblasts 
relative to fibroblasts elsewhere in the body (Furtado et al. 
2014), consistent with a potentially important role here.
Myocardial expression of H6PDH (Brereton 
et  al. 2001, Gomez­Sanchez et  al. 2008), and H6PDH 
immunoreactivity in cells identified as fibrocytes (Gomez­
Sanchez et  al. 2008), suggests that NADPH will be 
available to support oxo­reductase activity in the heart. 
However, conversion of 11­DHC to corticosterone is 
comparatively low in whole ventricular homogenate from 
mice and rats (Walker et al. 1991, Sheppard & Autelitano 
2002). Similarly, although HSD11B1 mRNA is present in 
human heart (Chai et al. 2010), cortisol is not significantly 
regenerated from cortisone infused in vivo into the hearts of 
patients undergoing elective coronary angiography (Iqbal 
et  al. 2014). Thus, although there is plentiful evidence 
that myocardial cells express 11β­HSD1, reactivation of 
glucocorticoid is apparently limited under physiological 
conditions. Nevertheless, our phenotyping studies in 
mice with genetically induced 11β­HSD1 deficiency show 
that 11β­HSD1 activity has a role in determining normal 
postnatal growth of the heart (Fig. 2 and below), as well as 
Ca2+ handling and diastolic function (White 2016).
11β-HSD1 in postnatal growth of  
the myocardium
GR activation during a prenatal surge in plasma 
glucocorticoid is essential for the structural and functional 
maturation of the heart before birth (Rog­Zielinska et al. 
2014, 2015), and consequently, genetic deletion of GR 
from the heart and smooth muscle results in increased 
perinatal mortality (Rog­Zielinska et  al. 2013, 2014). 
11β­HSD1 is not expressed to any extent in the mouse 
heart in the prenatal period (Speirs et  al. 2004), and 
neither global (Kotelevtsev et al. 1997) nor cardiomyocyte 
and vascular smooth muscle cell­specific (White et  al. 
2016) deletion of Hsd11b1 has any influence on perinatal 
mortality. However, a role for 11β­HSD1 in the maturation 
of the postnatal heart is indicated by our observation that 
hearts from adult mice with global deficiency of 11β­HSD1 
are smaller than those of wild­type mice (McSweeney 
2010, McSweeney et  al. 2010; Fig.  2A). Cardiomyocyte 



















































































Hearts from adult mice with global 11β-HSD1 
deficiency are hypomorphic and have shorter 
cardiomyocytes. Ultrasound analysis (A) reveals a 
significant reduction in left ventricular 
dimensions in 12-week-old Hsd11b1−/− (open bars) 
compared with control wild-type mice (filled 
bars). Reduction in heart size was confirmed 
when post-mortem heart weight was compared 
with body weight (B). LV dimensions 
(left ventricular end-diastolic area, solid red 
(Hsd11b1−/−) and black (control wild type), and 
left ventricular end-systolic area, hatched red 
(Hsd11b1−/−) and black (control wild type)) were 
not influenced by the loss of 11β-HSD1 from late 
gestation until 6 weeks of age (C). In adult hearts, 
there was no effect of 11β-HSD1 deficiency (red) 
on the distribution of cardiomyocyte cross-
sectional area (D), but the length of individual 
cardiomyocytes (E) isolated from Hsd11b1−/− 
hearts was significantly less than that isolated 
from control wild-type hearts (black).*P < 0.05, 
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g a gray and others 11β-HSD1 and the heart
from proliferative to hypertrophic growth (Richardson 
et al. 2016). MR activation in the same period promotes 
proliferation (Feng et  al. 2013). Proliferative neonatal 
cardiomyocytes can reactivate glucocorticoids through 
11β­HSD1 oxo­reductase activity during the period that 
they retain proliferative capacity (Lister et  al. 2006). 
However, the hearts of globally 11β­HSD1­deficient mice 
have normal ventricular dimensions from E18.5 to at least 
P40 (Fig.  2B). Mice with targeted deletion of 11β­HSD1 
in cardiomyocytes and vascular smooth muscle also 
have phenotypically normal hearts (White et  al. 2016). 
Therefore, loss of cardiomyocyte corticosteroid receptor 
activation in the perinatal period does not account for the 
smaller size of hearts in adult 11β­HSD1 mice. Interestin­
gly, further analysis revealed that although cardiomyocyte 
cross­sectional area is normal in adult hearts of 11β­HSD1­
deficient mice (Fig. 2C), cardiomyocyte length is reduced 
(Fig.  2D; White 2016). Cardiomyocytes are influenced 
by physical interactions and paracrine signalling from 
other cells in their environment. Blood volume and blood 
pressure are not modified in mice with global 11β­HSD1 
deficiency, so altered in vivo haemodynamic stress is not 
likely to underlie the reduction in cardiomyocyte length 
(White 2016). Further investigation is required to find 
whether the loss of 11β­HSD1 in other myocardial cells, 
for example, resident macrophages or fibroblasts can 
indirectly influence cardiomyocyte size during postnatal 
growth. In terms of clinical relevance, it is notable that 
a single nucleotide polymorphism in the HSD11B1 gene 
is also associated with reduced left ventricular mass 
(Rahman et al. 2011), although the underlying mechanism 
was not investigated.
11β-HSD1 and myocardial pathology
Although cellular 11β­HSD1 expression and activity may 
normally be low in the heart, both can change rapidly 
in response to external stimuli (reviewed in Chapman 
et  al. 2013b). Glucocorticoid itself promotes 11β­HSD1 
expression (Sai et al. 2008, Morgan et al. 2014), and there 
is good evidence that 11β­HSD1 is the major regulator 
of the tissue­specific effects of circulating glucocorticoid 
excess (Morgan et  al. 2014). The pro­inflammatory 
cytokines IL­1 and TNF­α are also key activators of 
11β­HSD1 gene expression, notably in fibroblasts (Hardy 
et al. 2006, Stegk et al. 2009, Ahasan et al. 2012, Chapman 
et al. 2013b, Esteves et al. 2014). These cytokines can act 
alone or synergistically with glucocorticoid (Kaur et  al.  
2010, Ahasan et al. 2012), to effect an increase in the capacity 
for intracellular glucocorticoid regeneration by 11β­HSD1. 
After trauma or injury, pro­inflammatory conditions that 
potently increase HPA axis activity (and thereby plasma 
11­DHC/cortisone levels (Harris et  al. 2001)), increased 
11β­HSD1 activity is likely to be a significant contributor 
to intracellular glucocorticoid levels and thus GR and 
MR activation. The generation of mice lacking 11β­HSD1 
(Kotelevtsev et  al. 1997, Holmes et  al. 2001) and more 
recently, the development of specific 11β­HSD1 inhibitors 
(Hughes et al. 2008, Wheelan et al. 2014, Sooy et al. 2015), 
have provided the opportunity to identify such roles for 
amplification of intracellular glucocorticoid signalling by 
11β­HSD1 in cardiac pathophysiology.
11β-HSD1, MI and heart failure
MI occurs most commonly after the formation of a 
clot on a ruptured atherosclerotic plaque, leading to 
ischaemic cardiomyocyte death in the area served by the 
affected coronary artery. As the adult heart has only very 
limited ability to regenerate, MI is followed by a period 
of wound healing that results in the formation of a scar 
to maintain myocardial integrity (Video 1; Frangogiannis 
2014). The extent of cardiomyocyte loss during ischaemia 
and expansion of injury during infarct repair are critical 
determinants of subsequent structural remodelling and 
functional deterioration leading to heart failure (Di Bella 
et al. 2013).
Video 1
Coronal view of mouse heart collected 7 days after 
induction of myocardial infarction and imaged by optical 
projection tomography, as we have described in 
(Zhao et al. 2015). Progressive optical sectioning through 
the heart reveals the extensive, thinned infarct area of 
the left ventricle. In 11β-HSD1 deficient mice the length of 
the infarcted area is reduced and the ventricle wall is less 
thinned (McSweeney et al. 2010, White 2016). View Video 
1 at http://movie-usa.glencoesoftware.com/video/10.1530/
JME-16-0128/video-1
In a preclinical model of atherosclerosis in ApoE­
deficient mice, pharmacological inhibition (Hermanowski­
Vosatka et  al. 2005), or genetic ablation (Garcia et  al. 
2013, Kipari et al. 2013), of 11β­HSD1 is associated with 
reduction in plaque size independently of changes in 
lipid availability. Plaque size reduction in ApoE/11β­
HSD1 double knockout mice was attributed to loss of 
11β­HSD1 in bone marrow­derived cells (Kipari et al. 2013). 
These cells are recruited to the arterial wall during plaque 
formation, where they accumulate lipid and contribute 
to the determination of plaque stability. Neutrophils, 
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g a gray and others 11β-HSD1 and the heart
(Zhang & Daynes 2007, Zhang et al. 2005), and expression 
is increased during their mobilisation and activation 
(reviewed in Chapman et  al. 2013b). Intracellular 
generation of glucocorticoid in monocyte/macrophages 
and neutrophils regulates their recruitment to sites of 
inflammation (Tiganescu et al. 2011), phagocytic potential 
(Speirs et  al. 2004) and the release of pro­inflammatory 
molecules (Zhang & Daynes 2007). 11β­HSD1 inhibition 
may therefore be of therapeutic benefit in preventing the 
development of complex plaques that are vulnerable to 
rupture causing MI.
Mice with global deficiency of 11β­HSD1 also have 
reduced structural and functional remodelling after MI, 
induced by coronary artery ligation, and do not go on to 
develop heart failure (McSweeney et al. 2010, White et al. 
2016). Thus, 11β­HSD1 availability has an impact not 
only on the development of coronary artery disease that 
leads to MI but also on the response of the myocardium 
after MI. Increased plasma corticosterone, derived from 
HPA axis activation in the immediate post­infarct period, 
reduces cardiomyocyte death and infarct size and there is 
evidence supporting roles for both GR (Hafezi­Moghadam 
et al. 2002) and MR (Mihailidou et al. 2009, Fraccarollo et al. 
2011) in determining this outcome. However, in 11β­HSD1­
deficient mice, plasma corticosterone is increased to the 
same extent after MI as in wild­type mice and infarct 
injury is unchanged (McSweeney et al. 2010). Therefore, 
differences in the immediate response to MI do not 
underlie the subsequent reduction in cardiac remodelling 
in the absence of 11β­HSD1. However, peri­infarct 
angiogenesis is enhanced in 11β­HSD1­deficient mice 
during repair (Small et  al. 2005), and this is associated 
with reduced infarct expansion in this period and with 
eventual scar size (McSweeney et al. 2010). Glucocorticoids 
suppress angiogenesis, and prevention of intracellular 
glucocorticoid regeneration in 11β­HSD1­deficient mice 
promotes angiogenesis in different in vitro and in vivo 
experimental models (Small et al. 2005). Smooth muscle 
cells are the main site of intravascular 11β­HSD1 activity 
(Hadoke et  al. 2013), but targeted deletion of Hsd11b1 
in cardiomyocytes and vascular smooth muscle cells 
failed to enhance angiogenesis or improve outcome after 
MI (White et  al. 2016). Engagement of extra­vascular 
pro­angiogenic mechanisms is therefore indicated. 
Increased angiogenesis in 11β­HSD1­deficient mice after 
MI is preceded by increased content of reparative ‘M2’ 
macrophages during the proliferative phase of wound 
healing (McSweeney et al. 2010). These ‘M2’ macrophages 
are essential for infarct repair (Shiraishi et al. 2016) and 
can release growth factors and pro­angiogenic mediators 
that increase neovascularisation during wound healing, 
as well as for promoting the formation of a mature 
collagen scar. Enhancement of macrophage polarisation 
in mice lacking 11β­HSD1 is therefore likely to be a key 
mechanism underlying improved outcome after MI 
(Fig. 3). Increased ‘M2’ polarisation of macrophages could 
occur due to loss of 11β­HSD1 in the inflammatory cells 
themselves, as proposed in atherosclerosis (Kipari et  al. 
2013), resulting in the modification of inflammatory 
cell recruitment and phenotype (Frangogiannis 2014). 
Figure 3
Distribution and actions of 11β-HSD1 in 
physiology and post-MI. In the healthy heart 
(panel A), 11β-HSD1 is expressed in 
cardiomyocytes (cm), vascular smooth muscle 
(VSMC) and fibroblasts (fib). Deletion of 
11β-HSD1 (panel B) results in smaller adult hearts 
and mild diastolic dysfunction (identified by 
increased deceleration time on Doppler mitral 
valve (MV) ultrasound). After MI (panel C), 
11β-HSD1 is additionally expressed in 
myofibroblasts (myofib) and recruited 
inflammatory cells (T cells, neutrophils (neut), 
monocyte (mono) and macrophages (mac)). 
11β-HSD1 deficiency after MI (panel D) results in 
increased early neutrophil (neut) recruitment, 
increased acquisition of pro-repair ‘M2’ 
macrophage (mac) phenotype, relative to 
pro-inflammatory ‘M1’ macrophage phenotype 
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g a gray and others 11β-HSD1 and the heart
Macrophage MR knockout (Usher et  al. 2010), or GR 
activation (Gratchev et  al. 2008), results in polarisation 
towards an ‘M2’ phenotype, and MR antagonists increase 
‘M2’ macrophage polarisation in the heart when given 
after MI (Fraccarollo et  al. 2008). Loss of glucocorticoid 
regenerative capacity in macrophages could therefore 
conceivably underlie changes in the activation status by 
preventing the activation of MR. However, promotion of 
peri­infarct angiogenesis after MI is enhanced when GR 
is blocked (Small et al. 2005), supporting a more indirect 
mechanism that involves GR, rather than MR activation.
Neutrophil recruitment is increased in the hearts 
of 11β­HSD1­deficient mice after the induction of MI 
(McSweeney et  al. 2010) (Fig.  3). This results at least in 
part from loss of 11β­HSD1 in neutrophils themselves, 
where its activity restrains recruitment to inflamed tissues 
through modulation of adhesion molecule availability 
at the cell surface (Cavalcanti et al. 2006, Tiganescu et al. 
2011, Coutinho et  al. 2016). Loss of 11β­HSD1 activity 
in the heart itself is also likely to contribute. Expression 
of neutrophil chemoattractants, including CXCL5/LIX 
(Smith & Herschman 1995), IL­6 (Hardy et al. 2006) and 
CXCL2/MIP2α (Uhlenhaut et  al. 2013) is repressed by 
glucocorticoid, and these chemoattractants are expressed 
by cells in the heart that express 11β­HSD1, including 
fibroblasts. Mast cell degranulation after myocardial 
injury also enhances neutrophil recruitment, and as 
degranulation is increased in the absence of 11β­HSD1 
(Coutinho et al. 2013), these cells may also play a role in 
increasing neutrophil recruitment in 11β­HSD1­deficient 
mice. In the post­infarct heart, neutrophils phagocytose 
necrotic myocytes and break down the intracellular 
matrix during the initial inflammatory phase of repair. 
However, they also promote the transition to resolution 
by releasing gelatinase­associated lipocalin (Horckmans 
et al. 2016). Efferocytosis, or macrophage engulfment of 
apoptotic cells, including neutrophils (Wan et al. 2013), 
will also enhance the acquisition of an ‘M2’ phenotype. 
Early enhancement of neutrophil recruitment may thus 
be an essential prerequisite for the promotion of repair in 
the mice lacking 11β­HSD1.
Several lines of evidence point to cardiac fibroblasts, 
particularly their high expression of 11β­HSD1 (Furtado 
et  al. 2014), as a key site for intracellular regeneration 
of glucocorticoid in the healing myocardial infarct 
(Chen & Frangogiannis 2013). 11β­HSD1 activity in 
stromal cells elsewhere, including synovial fibroblasts, 
is promoted by the action of corticosteroids and 
inflammatory mediators (Hardy et  al. 2006, Ahasan 
et  al. 2012). In the skin, 11β­HSD1 is active in dermal 
fibroblasts (Tiganescu et al. 2011) and global 11β­HSD1 
knockout or pharmacological inhibition promotes skin 
wound healing (Tiganescu et  al. 2013). Fibroblasts are 
abundant in the heart and have multiple potential roles 
during myocardial inflammation and repair that follows 
MI (Porter & Turner 2009). In addition to the production 
of collagen and other matrix proteins that determine 
scar integrity, they secrete molecules, including cyto­
kines, prostaglandins (Shinde & Frangogiannis 2014, 
Fernando et  al. 2015, Turner 2016) and microRNA 
(Fang & Yeh 2015), capable of regulating inflammation 
(Porter & Turner 2009, Chen & Frangogiannis 2013, 
van Nieuwenhoven & Turner 2013), Treg recruitment 
(Frangogiannis 2014), angiogenesis (Newman et al. 2011), 
cardiogenesis (Furtado et  al. 2014) and hypertrophy 
(Abonnenc et  al. 2013, Cartledge et  al. 2015). The 
role of cardiac fibroblast 11β­HSD1 in regulating the 
cellular secretome and on the response to MI and other 
pathological challenges merits further investigation.
Therapeutic potential of 11β-HSD1 inhibition 
in myocardial disease
Pharmacological inhibitors of 11β­HSD1 have already been 
developed for use in metabolic disease and for prevention 
of cognitive decline (Anderson & Walker 2013, Sooy et al. 
2015). Survival after MI is increasing, thanks to prompt 
and efficient intervention to restore perfusion to the 
ischaemic myocardium (BHF Heart Stats, 2015). However, 
patients survive with damage to their myocardium 
that spreads to the peri­infarct area during wound 
healing. Thus, although the introduction of coronary 
revascularisation has been associated with a reduction in 
early post­MI deaths, there has been an increase in the 
5­year incidence of HF (Velagaleti et al. 2008). Preclinical 
data are highly supportive of the therapeutic potential of 
11β­HSD1 inhibitors in the prevention of atherosclerosis 
(Hermanowski­Vosatka et al. 2005, Garcia et al. 2013, Kipari 
et  al. 2013), as well as acutely following MI, to prevent 
the infarct expansion that promotes the development of 
heart failure (McSweeney et al. 2010, White et al. 2016). 
Ventricular hypertrophy is a feature of the adaptive 
ventricular remodelling that follows MI and in pressure 
overload associated with hypertension. Gordon and 
coworkers (2014) showed that an inhibitor of 11β­HSD1 
was able to reverse established hypertrophy and associated 
dysfunction in a mouse model of perfusion deficit­
induced cardiac remodelling. Interestingly, this outcome 
was independent of any influence on neovascularisation 
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have additional benefits on post­MI remodelling beyond 
the prevention of infarct expansion. In clinical trials of 
11β­HSD1 inhibitors in diabetes, improvement in blood 
glucose and other metabolic end points failed to reach 
significance when compared with existing therapies, but 
the evidence for a modest benefit was highly consistent 
(Anderson & Walker 2013). Such benefits in metabolic 
outcomes are likely to be advantageous in patients with 
cardiovascular disease. Together, these data demonstrate 
the potential for ‘repurposing’ of 11β­HSD1 inhibitors 
already developed for clinical use in other therapeutic 
areas. None of the trials of these inhibitors in diabetes 
have raised any question on the effectiveness of target 
engagement or on toxicology. Improved understanding 
of the cellular mechanisms through which 11β­HSD1 
inactivation enhances angiogenesis prevents infarct 
expansion, and adverse ventricular remodelling will help 
to justify the clinical development of 11β­HSD1 inhibitors 
for MI therapy, as well as providing biomarkers to monitor 
the effects of 11β­HSD1 inhibition.
MR antagonists are already used effectively in the 
treatment of heart failure (Pitt et al. 1999, Zannad et al. 2011, 
2012), by preventing MR activation in cardiomyocytes 
(Fraccarollo et al. 2011) and in macrophages (Fraccarollo 
et al. 2008). Preclinical studies have revealed the potential 
benefits of blocking GR in cardiovascular disease (Small 
et  al. 2005, Oakley & Cidlowski 2015, Richardson et  al. 
2016), but essential physiological roles of GR activation 
preclude the use of GR antagonists in vivo. With their 
distinct profile of action, 11β­HSD1 inhibitors offer an 
alternative means of regulating GR and MR activation 
in specific cells. 11β­HSD1 inhibitors might provide an 
alternative to MR antagonists in patients who do not 
tolerate the effects of MR antagonism on K+ handling 
(Pitt et al. 2008). Alternatively, they may have additional 
or complementary benefits when combined with MR 
antagonists, and this should be tested in models of 
cardiovascular disease.
In this review, we have considered 11β­HSD1 in the 
context of its capacity for intracellular regeneration of 
active glucocorticoids from inert metabolites. However, 
11β­HSD1 has other actions that may contribute to the 
physiological and pathophysiological outcomes reported 
previously. 11β­HSD1 is a multifunctional carbonyl 
reductase that also converts 11­ and 7­oxosterols into the 
respective 7­hydroxylated forms and also catalyses the 
reduction of non­steroidal xenobiotics (Mitic et al. 2013b, 
Odermatt & Klusonova 2015). Studies with selective 
inhibitors and genetically modified mice provide further 
evidence for the effects of 11β­HSD1 in the regulation 
of cellular cholesterol flux and on bile acid homeostasis 
(Mitic et  al. 2013a). Oxysterols influence vascular 
function (Mitic et  al. 2013a), and modulation of genes 
involved in cellular cholesterol flux is associated with 
disease severity in patients after MI (Suresh et al. 2014). 
These mechanisms may therefore be engaged alongside 
prevention of intracellular glucocorticoid regeneration 
when 11β­HSD1 is genetically depleted or inhibited 
and could contribute to any beneficial effects of drug 
intervention in cardiovascular pathology.
Conclusion
Studies over the past three decades have demonstrated 
roles for the 11β­HSD enzymes in metabolic, neurological 
and inflammatory diseases, but roles in the heart have 
been relatively unexplored. Recent studies have shown 
that 11β­HSD1 is expressed in myocardial cells, including 
notably cardiac fibroblasts. Global 11β­HSD1 deficiency 
has effects on cardiac growth and physiological function 
that are more subtle than those associated with GR deletion 
(Oakley & Cidlowski 2015, Richardson et  al. 2016), or 
adrenalectomy (Cruz­Topete et al. 2016), but nevertheless 
of physiological relevance. Importantly, genetic or 
pharmacological depletion of 11β­HSD1 also prevents 
adverse cardiac remodelling and the development of heart 
failure after MI (McSweeney et  al. 2010, Gordon et  al. 
2014, White et al. 2016). In the skin, 11β­HSD1 expression 
is increased during ageing (Tiganescu et  al. 2011) and 
11β­HSD1 inhibition prevents age­induced structural 
defects (Tiganescu et  al. 2013). If 11β­HSD1 expression 
is similarly increased in the heart, the influence of 
11β­HSD1 on myocardial physiology and pathophysiology 
is likely to be even more pronounced in the aged heart. 
Novel mass spectrometry imaging has recently permitted 
accurate localisation of 11β­HSD1 ‘intracrinology’ in 
sections of mouse adrenal gland and brain (Cobice et al. 
2013). Application of mass spectrometry imaging to the 
heart will be of significant value to understand cellular 
11β­HSD1 activity and how it is changed in ageing and 
disease. Whether the key intracellular mechanisms of 
11β­HSD1 are dependent or independent of glucocorti­
coid regeneration, preclinical studies have started to 
reveal novel therapeutic potential for drugs that inhibit 
11β­HSD1. Given that 11β­HSD1 expression and activity 
can be rapidly increased by inflammatory mediators 
and by glucocorticoids, there are likely to be further 
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as  well as in preventing the deterioration of cardiac 
function associated with chronic stress, Cushing’s 
disease and glucocorticoid therapy (Souverein et al. 2004, 
Wei  et  al. 2004, Peppa et  al. 2009, Kumari et  al. 2011, 
Shibusawa et al. 2015, Frustaci et al. 2016).
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